{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:50:55Z","timestamp":1774367455930,"version":"3.50.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Primary Sj\u00f6gren\u2019s syndrome (pSS) is an autoimmune disorder characterized by xerostomia and keratoconjunctivitis sicca, with approximately 10%\u201320% of patients developing concurrent immune thrombocytopenia (ITP). Recent studies suggest the pathogenesis of primary Sj\u00f6gren\u2019s syndrome - associated immune thrombocytopenia (pSS-ITP) may involve dysregulated TLR7 signaling, B-cell hyperactivation, and autoantibody-mediated platelet destruction. Beyond conventional therapies (e.g., glucocorticoids and intravenous immunoglobulin [IVIG]), emerging treatments have garnered increasing attention, including thrombopoietin receptor agonists (TPO-RAs), B-cell\u2013targeted therapies, and mTOR inhibitors. Predictive models incorporating bone marrow megakaryocyte counts and autoantibody profiles may facilitate individualized treatment selection. Future multicenter clinical studies are warranted to evaluate the long-term efficacy and safety of novel agents and to explore biomarker-guided precision therapy. This review systematically summarizes the pathophysiological mechanisms of pSS- ITP, synthesizes current clinical treatment strategies, and highlights key biomarkers with potential implications for therapeutic response, aiming to provide a theoretical foundation and practical guidance for optimizing individualized therapeutic regimens.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1748373","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:58:29Z","timestamp":1772607509000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary Sj\u00f6gren\u2019s syndrome-associated immune thrombocytopenia: from pathogenesis to treatment"],"prefix":"10.3389","volume":"17","author":[{"given":"Ziqiang","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Central Hospital of Dalian University of Technology","place":["Dalian, China"]},{"name":"Graduate School, Dalian Medical University","place":["Dalian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taoyuan","family":"He","sequence":"additional","affiliation":[{"name":"Graduate School, Dalian Medical University","place":["Dalian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guixiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Second Hospital of Longyan","place":["Longyan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohua","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Second Hospital of Longyan","place":["Longyan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Central Hospital of Dalian University of Technology","place":["Dalian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann rheumatic Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/jir.S414320","article-title":"Nomogram based on inflammatory factor to predict therapeutic response of thrombocytopenia in patients with primary sjogren's syndrome","volume":"16","author":"Gan","year":"2023","journal-title":"J Inflammation Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1623774","article-title":"CD226 (+) B cells in primary Sjogren's syndrome: a key player in clinical manifestations and disease pathogenesis","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/8hgmjm","article-title":"Factors associated with secondary immune thrombocytopenia in patients with primary Sj\u00f6gren's syndrome: a retrospective study of 639 cases","author":"Jing","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000037909","article-title":"Comprehensive analysis of the clinical manifestations and hematological parameters associated with secondary immune thrombocytopenia in patients with primary Sj\u00f6gren syndrome: An observational study","author":"Wenwen","year":"2024","journal-title":"Medicine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00138","article-title":"Clinical characteristics of secondary immune thrombocytopenia associated with primary sjogren's syndrome","volume":"7","author":"Dai","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110716","article-title":"Characteristics and treatment responses of immune thrombocytopenia in patients with primary Sj\u00f6gren syndrome","author":"Feng","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4312-y","article-title":"Severe thrombocytopenia in connective tissue diseases: a single-center review of 131 cases","author":"Wei","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211020179","article-title":"Ten-year survival analysis of patients with primary Sjogren's syndrome in China: a national prospective cohort study","volume":"13","author":"Qian","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.53730\/ijhs.v6nS5.10626","article-title":"Immune thrombocytopenia: an updated review from etiopathophysiology, laboratory investigations and current therapy","volume":"6","author":"Mazumder","year":"2022","journal-title":"Int. J. Health Sci."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/00368504221102786","article-title":"Eltrombopag improves refractory thrombocytopenia in patients with Sjogren's syndrome","volume":"105","author":"Xu","year":"2022","journal-title":"Sci Prog"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05152-x","article-title":"Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study","author":"Fangfang","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.12659\/msm.895144","article-title":"Elevated plasma P-selectin autoantibodies in primary sj\u00f6gren syndrome patients with thrombocytopenia","author":"Yahui","year":"2015","journal-title":"Med Sci Monitor"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06818-y","article-title":"Elevated plasma levels of specific antiplatelet glycoprotein autoantibodies in patients with primary Sjogren syndrome with thrombocytopenia","volume":"43","author":"Ruan","year":"2024","journal-title":"Clin Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637659","article-title":"Activation of toll-like receptor 7 signaling pathway in primary sjogren's syndrome-associated thrombocytopenia","volume":"12","author":"Zhang","year":"2021","journal-title":"Frontiersinimmunology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01075","article-title":"The toll for trafficking: toll-like receptor 7 delivery totheEndosome","volume":"8","author":"Petes","year":"2017","journal-title":"Frontiersinimmunology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41467-017-01687-x","article-title":"TLR7 mediated viral recognition results in focal type I interferon secretion by dendritic cells","volume":"8","author":"Saitoh","year":"2017","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s10020-020-00256-1","article-title":"Escape from X chromosome inactivation and female bias of autoimmune diseases","volume":"26","author":"Mousavi","year":"2020","journal-title":"Mol Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.123","article-title":"TLR7, a third signal for the robust generation of spontaneous germinal center B cells in systemic lupus erythematosus","volume":"15","author":"Fan","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1665086","article-title":"B cell subpopulations and their role in the pathogenesis of primary Sjogren's syndrome: insights from single- cell RNA sequencing","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103820","article-title":"Recent advances in the mechanisms and treatment of immunethrombocytopenia","volume":"76","author":"Provan","year":"2022","journal-title":"EBioMedicine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood-2013-11-536003","article-title":"Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis","volume":"124","author":"Koupenova","year":"2014","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrrheum.2018.38","article-title":"The non-haemostatic role of platelets in systemic lupus erythematosus","volume":"14","author":"Linge","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41392-025-02198-8","article-title":"Platelets and diseases: signal transduction and advances in targeted therapy","volume":"10","author":"Tian","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.7.2612","article-title":"Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis","volume":"99","author":"Viallard","year":"2002","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2367","article-title":"Platelet-associated CD154 in immune thrombocytopenic purpura","volume":"105","author":"Solanilla","year":"2005","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.087874","article-title":"Patient autoantibodies induce platelet destruction signals via raft-associated glycoprotein Ibalpha and Fc RIIa in immune thrombocytopenia","volume":"98","author":"Urbanus","year":"2013","journal-title":"Haematologica"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.10420","article-title":"Autoantibody to c - Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia","volume":"46","author":"Kuwana","year":"2002","journal-title":"Arthritis Rheumatism"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.08.021","article-title":"Anti-c-Mpl antibodies in immune thrombocytopenia suppress thrombopoiesis and decrease response to rhTPO","volume":"170","author":"Jing","year":"2018","journal-title":"Thromb Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004974","article-title":"FcgammaRIIA expression accelerates nephritis and increases platelet activation in systemiclupuserythematosus","volume":"136","author":"Melki","year":"2020","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15265","article-title":"Platelet FcgammaRIIA in immunity and thrombosis: Adaptive immunothrombosis","volume":"19","author":"Patel","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12935","article-title":"Fc\u03b3 receptor expression on splenic macrophages in adult immunethrombocytopenia","volume":"188","author":"Audia","year":"2017","journal-title":"ClinExpImmunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-295477","article-title":"High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcgamma receptors on monocytes in patients with primary immune thrombocytopenia","volume":"117","author":"Liu","year":"2011","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae973","article-title":"Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/cmmkod","article-title":"Role of TLR7 in the pathogenesis of primary Sj\u00f6gren's syndrome","volume":"42","author":"Song","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2012.19.6.341","article-title":"Treatment with high dose dexamethasone of severe thrombocytopenia in primary sj\u00f6gren's syndrome","volume":"19","author":"Jun","year":"2012","journal-title":"J Rheumatic Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2344-x","article-title":"High-dose methylprednisolone pulse therapy upregulated Fc\u03b3RIIb expression on B cells in primary Sj\u00f6gren's syndrome patients with thrombocytopenia","author":"Haifeng","year":"2013","journal-title":"Clin Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1395-4","article-title":"Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sj\u00f6gren's syndrome","author":"Bum-Su","year":"2012","journal-title":"Rheumatol Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12467","article-title":"New aspects on the efficacy of high-dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia","volume":"112","author":"Mayer","year":"2017","journal-title":"Vox Sang"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.7180\/kmj.2017.32.1.118","article-title":"A case of treatment with steroid and hydrochloroquine of thrombocytopenia inPrimarySj\u00f6gren'sSyndrome","author":"Yeong Seop","year":"2017","journal-title":"Kosin Med J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate mofetil for first-line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury","year":"2021","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.14707","article-title":"Predictive value of bone marrow megakaryocyte count for immunotherapeutic response in primary Sj\u00f6gren's syndrome patients with severe immune thrombocytopenia: A single-center case\u2013control study in China","author":"Hui","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"9615","DOI":"10.3390\/ijms22179615","article-title":"Megakaryopoiesis and platelet biology: roles of transcription factors and emerging clinical implications","volume":"22","author":"Noh","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1159\/000524535","article-title":"The association between P-selectin autoantibody positive and response to steroid treatment in newly diagnosed immune thrombocytopenia patients","author":"Li","year":"2022","journal-title":"Acta Haematologica"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000677","article-title":"Predictors of refractory risk in systemic lupus erythematosus-related thrombocytopenia: a dual-centre retrospective study","volume":"9","author":"Su","year":"2022","journal-title":"Lupus Sci Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1606510","article-title":"The predictive value of NLR, SII, and complement 3 in treatment response for systemic lupus erythematosus with immune thrombocytopenia","volume":"16","author":"Zheng","year":"2025","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/rheumatology\/kead160","article-title":"Sirolimus for the treatment of patients with refractory connective tissue disease-related thrombocytopenia: a pilot study","volume":"63","author":"Du","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B50","article-title":"The efficacy and safety of low- dose rituximab in treatment of primary Sj\u00f6gren's syndrome with thrombocytopenia","author":"Li","year":"2012","journal-title":"Chin J Internal Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/rhu.0000000000000273","article-title":"Efficacy and safety of rituximab in systemic lupus erythematosus and sj\u00f6gren syndrome patients with refractory thrombocytopenia: A retrospective study of 21 cases","author":"Bin","year":"2015","journal-title":"Jcr-journal Clin Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101036","article-title":"Preclinical characterization of the Toll-like receptor 7\/8 antagonist MHV370 for lupus therapy","volume":"4","author":"Hawtin","year":"2023","journal-title":"Cell Rep Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.3c00136","article-title":"Discovery of the TLR7\/8 antagonist MHV370 for treatment of systemic autoimmune diseases","volume":"14","author":"Alper","year":"2023","journal-title":"ACS Med Chem Lett"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121162","article-title":"An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmunediseases","volume":"609","author":"Wu","year":"2021","journal-title":"IntJ Pharm"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07039.x","article-title":"The effect of anti-CD40 ligand in immune thrombocytopenic purpura","volume":"141","author":"Patel","year":"2008","journal-title":"Br J Haematol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41577-023-00834-4","article-title":"The role of platelets in immune-mediated inflammatory diseases","volume":"23","author":"Scherlinger","year":"2023","journal-title":"Nat Rev Immunol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1827822","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1748373\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:52:25Z","timestamp":1774363945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1748373\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2026.1748373"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1748373","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"1748373"}}